Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans

Journal of Clinical Pharmacology

Volumn 37, Issue 8, 1997, Pages 693-703

  Kaplan, Gary B ^a,b,c   Greenblatt, David J ^b   Ehrenberg, Bruce L ^b   Goddard, Jill E ^b   Cotreau, Monette M ^b   Harmatz, Jerold S ^b   Shader, Richard I ^b  

^a BROWN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HEART PALPITATION; HUMAN; NAUSEA; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SWEATING;

EID: 0030807271     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04356.x     Document Type: Article

References (39)

1. Barone JJ, Roberts HR: Caffeine consumption. Food Chem Toxicol 1996;34:119-129.
2. Stavric B, Klassen R, Watkinson B, Karpinski K, Stapley R, Fried P: Variability in caffeine consumption from coffee and tea: possible significance for epidemiological studies. Food Chem Toxicol 1988;26:111-118.
3. Sawynok J: Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49:37-50.
4. Bättig K, Welzl H: Psychopharmalogical profile of caffeine. In, Garrattini S (ed.): Caffeine Coffee and Health. New York: Raven Press, 1993;213-253.
5. Nehlig A, Daval J-L, Debry G: Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 1992;17:139-170.
6. Lader MH, Bruce MS: The human psychopharmacology of the methylxanthines. In, Hindmarch I, Stoner PD (eds.): Human Psychopharmacology: Measures and Methods. Philadelphia: Wiley, 1989:179-200.
7. Griffiths RR, Woodson PP: Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology 1988;94:437-451.
8. Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992;327:1109-1114.
9. Holtzman S: Caffeine as a model drug of abuse. Trends Pharmacol Sci 1990;11:355-356.
10. Heishman SJ, Henningfield JE: Stimulus functions of caffeine in humans: relation to dependence potential. Neurosci Biobehav Rev 1992;16:273-287.
11. Daly JW: Adenosine receptors: targets for future drugs. J Med Chem 1982;25:197-207.
12. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW: Adenosine receptors and behavioral actions of methylxanthines. Prod Natl Acad Sci USA 1981;78:3260-3264.
13. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G Shader RI: Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology 1992;6:145-153.
14. Zwyghuizen-Doorenbos A, Roehrs TA, Lipschutz L, Timms V, Roth T: Effects of caffeine on alertness. Psychopharmacology 1990;100:36-39.
15. Lieberman HR, Wurtman RJ, Emde GG, Coviella ILG: The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 1987;7:315-320.
16. Bruce M, Scott N, Lader M, Marks V: The psychopharmalogical and electrophysiological effects of single doses of caffeine in healthy human subjects. Br J Clin Pharmacol 1986;22:81-87.
17. Dimpfel W, Schober F, Spüler M: The influence of of caffeine on human EEG under resting conditions and during mental loads. Clin Invest 1993;71:197-207.
18. Clubley M, Bye CE, Henson TA, Peck AW, Riddington CJ: Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity. Br J Clin Pharmacol 1979;7:157-163.
19. Hasenfratz M, Bättig K: Acute dose-effect relationships of caffeine and mental performance. EEG, cardiovascular and subjective parameters. Psychopharmacology 1994;114:281-287.
20. Kaplan GB, Greenblatt DJ, LeDuc BW, Thompson ML, Shader RI: Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther 1989;248:1078-1083.
21. Kaplan GB, Tai NT, Greenblatt DJ, Shader RI: Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology 1990;101:539-544.
22. Brockwell NT, Eikelboom R, Beninger RJ: Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 1991;38:513-517.
23. Mattila M, Seppala T, Mattila MJ: Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Pharmacol 1988;3:215-229.
24. Charney DS, Galloway MP, Heninger GR: The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans. Life Sci 1984;35:135-144.
25. Charney DS, Heninger GR, Jatlow PI: Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 1985;42:233-243.
26. Bruce M, Scott N, Shine P, Lader M: Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen Psychiatry 1992;49:867-869.
27. Newman F, Stein MB, Trettau JR, Coppola R, Uhde TW: Quantitative electroencephalographic effects of caffeine in panic disorder. Psychiatry Res 1992;106:90-96.
28. Bartel P, Delport R, Lotz B, Ubbink J, Becker P: Effects of single and repeated doses of theophylline on aspects of performance, electrophysiology and subjective assessments in healthy human subjects. Psychopharmacology 1992;106:90-96.
29. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, Shader RI: Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989;250:134-140.
30. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al: Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with kotoconazole. J Pharmacol Exp Ther 1996;276:370-379.
31. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI: Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-1698.
32. DiMascio A, Havens LL, Klerman GL: The psychopharmacology of phenothiazine compounds. J Nerv Ment Dis 1963;136:15-28,168-186.
33. Kennedy JS, LeDuc BW, Scavone JM, Harmatz JS, Shader RI, Greenblatt DJ: The pharmacokinetics of intravenous caffeine: comparison of high performance liquid chromatographic and gas chromatographic methods. J Chromatogr 1987;422:274-280.
34. Kennedy JS, von Moltke LL, Harmatz JS, Engelhardt N, Greenblatt DJ: Validity of self-reports of caffeine use. J Clin Pharmacol 1991;31:677-680.
35. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, et al: Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994;47:1767-1776.
36. Denaro CP, Brown CR, Wilson M, Peyton J, Benowitz NL: Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990;48:277-285.
37. Kamimori GH, Lugo SI, Penetar DM, Chamberlain AC, Brunhart GE, Brunhart AE, Eddington ND: Dose-dependent caffeine pharmacokinetics during severe sleep deprivation in humans. Int J Clin Pharmacol Ther 1995;32:182-186.
38. Benowitz NL, Peyton J, Mayan H, Denaro CP: Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995;58:684-691.
39. Murphy TL, McIvor C, Yap A, Cooksley WGE, Halliday JW, Powell LW: The effect of smoking on caffeine elimination: implications for its use as a semiquantitative test of liver function. Clin Exp Pharmacol Physiol 1988;15:9-13.